Guerrilla RF, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Guerrilla RF, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.85M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.81M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.77M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.14M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $5.18M | Apr 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.99M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($10.75M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.97M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($12.03M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($2.84M) | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | ($17.9K) | Apr 28, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.66M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.76M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($12.92M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($11.12M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($3.67M) | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | ($17.9K) | Apr 28, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.55M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.71M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.28M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.11M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.59M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $3.59M | Apr 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10M | Mar 26, 2026 |
| FY2025 | Sep 30, 2025 | $900.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($6.65M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($13.45M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($9.25M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($4.82M) | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | ($13.0K) | Apr 28, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $380.9K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $101.7K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $549.9K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $393.4K | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $310.7K | Apr 1, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.50M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.92M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.01M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.66M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $10.63M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $3.96M | Apr 1, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.66M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.11M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $25.81M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.31M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.72M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $7.09M | Apr 1, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.18M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($12.22M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | ($6.80M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.35M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.92M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($3.13M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2019 | ($1.64M) | Apr 1, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.78M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($53.79M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($43.04M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($27.07M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($15.05M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($12.21M) | Apr 1, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $9.6K | Apr 28, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 3, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.60M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 10.24M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 7.89M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 6.21M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 33.22M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 2.27M | Apr 1, 2022 |